title: An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant.
abstract: The ability of various human derived in vitro systems to predict various aspects of the in vivo metabolism and kinetics of almokalant have been investigated in a multicenter collaborative study. Although almokalant has been withdrawn from further clinical development, its metabolic and pharmacokinetic properties have been well characterized. Studies with precision-cut liver slices, primary hepatocyte cultures, and hepatic microsomal fractions fortified with UDP-glucuronic acid all suggested that almokalant is mainly glucuronidated to the stereoisomers M18a and M18b, which is in good agreement with the results in vivo. Both in vivo and in vitro studies indicate that the formation of M18b dominates over that of M18a, although the difference is more pronounced with the in vitro systems. Molecular modeling, cDNA-expressed enzyme analysis, correlation analysis, and inhibition studies did not clearly indicate which P450 enzymes catalyze the oxidative pathways, which may indicate a problem in identifying responsible enzymes for minor metabolic routes by in vitro methods. All of the in vitro systems underpredicted the metabolic clearance of almokalant, which has previously been reported to be a general problem for drugs that are cleared by P450-dependent metabolism. Although few studies on in vivo prediction of primarily glucuronidated drugs have appeared, in vitro models may consistently underpredict in vivo metabolic clearance. We conclude that in vitro systems, which monitor phase II metabolism, would be beneficial for prediction of the in vivo metabolism, although all of the candidate liver-derived systems studied here, within their intrinsic limitations, provided useful information for predicting metabolic routes and rates.
authors: Drug Metabolism and Pharmacokinetics and Bioanalytical Chemistry, AstraZeneca Research and Development, Mölndal, S-431 83 Mölndal, Sweden. tommy.b.andersson@astrazeneca.com
authors: T B
authors: TB
authors: Andersson
authors: H
authors: H
authors: Sjöberg
authors: K J
authors: KJ
authors: Hoffmann
authors: A R
authors: AR
authors: Boobis
authors: P
authors: P
authors: Watts
authors: R J
authors: RJ
authors: Edwards
authors: B G
authors: BG
authors: Lake
authors: R J
authors: RJ
authors: Price
authors: A B
authors: AB
authors: Renwick
authors: M J
authors: MJ
authors: Gómez-Lechón
authors: J V
authors: JV
authors: Castell
authors: M
authors: M
authors: Ingelman-Sundberg
authors: M
authors: M
authors: Hidestrand
authors: P S
authors: PS
authors: Goldfarb
authors: D F
authors: DF
authors: Lewis
authors: L
authors: L
authors: Corcos
authors: A
authors: A
authors: Guillouzo
authors: P
authors: P
authors: Taavitsainen
authors: O
authors: O
authors: Pelkonen
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000378:metabolism* / Q000493:pharmacokinetics; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism*; D011412:Propanolamines / Q000378:metabolism* / Q000493:pharmacokinetics
chemical_list: D000889:Anti-Arrhythmia Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D011412:Propanolamines; D003577:Cytochrome P-450 Enzyme System; C074334:almokalant